This inventor holds 1 USPTO granted patent. Top assignees: Genecentric Therapeutics, Inc., The University of North Carolina at Chapel Hill. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 10 
1 out of 1,331 
Years Active: 2026
Title: Michael Milburn: Cancer Research and FGFR3 Inhibitor Patents
Introduction
Michael Milburn is an inventor associated with Durham, North Carolina, and research involving cancer treatment. His work includes a patent describing methods for selecting and treating cancer with FGFR3 inhibitors.
Latest Patents
Milburn is listed as an inventor on 1 patent, titled “Methods for Selecting and Treating Cancer with FGFR3 Inhibitors.” The patent describes FGFR3 activation signatures that may help predict whether a person with cancer will respond to FGFR3 inhibitor therapy.
Career Highlights
Milburn’s listed affiliations include Genecentric Therapeutics, Inc., and The University of North Carolina at Chapel Hill. These affiliations connect his work with biotechnology and academic research.
Collaborations
His listed collaborators include Charles M. Perou and Joel Eisner, whose work is also associated with cancer research and therapeutic development.
Conclusion
Michael Milburn’s patent focuses on using FGFR3 activation signatures to guide the selection of cancer patients for inhibitor therapy, reflecting an effort to support more targeted treatment decisions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile